Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced successful results ...

Mood and anxiety disorders represent a leading cause of disability worldwide. Current first-line pharmacological treatments, ...

VANCOUVER, BC / ACCESS Newswire / June 30, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce, further to its news ...

Study designed to evaluate performance and formulation stability of proprietary nose-to-brain delivery system SARASOTA, FLA., June 29, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) ("Silo" or ...

Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including ...

Publication Highlights Novel Intravenous Everolimus Formulation and Demonstrates Broad Potential of Deciparticle™ Technology for Hydrophobic ...

According to the company, the product has been developed in gummy form as part of its approach to consumer-friendly ...

There is growing tension at Red Bull with Max Verstappen still to commit his future to the F1 giants, according to reports from the Netherlands. Verstappen has stated that his visit last week to Red ...

No treatment-related serious adverse events observed in either treatment group; no treatment-related tolerability issues or discontinuations reported during the interim analysis period WESTLAKE ...

Summertime hikes and afternoons in the backyard can be ruined by mosquito bites. So, many people apply topical synthetic repellents like DEET before heading outside, but there is a growing market for ...

Abstract: Parallelization is widely employed to improve the exploration ability of controllers. However, it is rare to provide a lightweight scheme for reducing homogeneous policies with theoretical ...

Ischaemic optic neuropathy (ION) is a rare but vision-threatening complication recently linked to GLP-1 receptor agonists, particularly semaglutide. Using over 30 million reports from the FDA Adverse ...